Participants receiving semaglutide showed nearly a 50% reduction in alcohol consumptionan effect size equal to or greater than seen with FDA-approved medications for AUD, like naltrexone, acamprosate, and disulfiram
Some people lose weight quickly, while others see slower progress or hit frustrating plateaus along the way
It supports keeping patients on therapies that benefit their health whenever it is safe to do so.
In most experimental settings, SGLT2i directly reduced inflammation and/or oxidative stress in various cardiac cell types under various pathological conditions such as high-fat diet, hyperglycemia, ischemia/reperfusion, LPS, DOXO, IL-1a/b, TNFa, IL-17a and Ang II